Normative Values for Peripheral Muscle Strenght in Critical Patients and Healthy Individuals (HHD-ICU)

March 12, 2024 updated by: Shirley Lima Campos, University of Pernambuco

Analysis of Peripheral Muscle Strength Measurement Methods in Healthy Individuals and Critical Patients: A Health Technology Assessment

Muscle strength is an important indicator of overall health and is a factor that has been associated with increased mortality in critical patients. Its measurement must be reliable and reproducible to ensure a quality outcome for clinical applicability. Recently, the use of digital handheld dynamometers in intensive care has gained support; however, analysis becomes challenging due to the absence of standardized reference equations for the Brazilian population. The aim of this study is to develop reference equations for the Brazilian population and define specific cutoff points for men, women, healthy individuals, and critical patients.

Study Overview

Status

Recruiting

Detailed Description

For this 3-year observational study, the population will consist of adult and elderly individuals of both sexes; for the healthy sample, patients without barriers to the assessment of peripheral muscle strength will meet the inclusion criteria, specifically, areas with wounds/dressings, burns, segments with fractures, or immobilization devices, while, for the critical patient population, the sample will comprise patients who are hospitalized in the Intensive Care Unit (ICU).

In the case of assessing healthy participants, an evaluation of the musculoskeletal system will be conducted to measure muscle strength (handgrip dynamometry and peripheral hand held muscle dynamometry). Additionally, the level of physical activity (International Physical Activity Questionnaire - Short Form) will also be assessed in the . Regarding critical patients, if the participant meets the criteria, the evaluation protocol will be carried out, which includes peripheral muscle strength assessment (Medical Research Council scale, Hand Dynamometer, and the Hand-Held Dynamometer) and the patient's mobility status (Perme ICU Mobility Score).

Daily screening will take place in the ICU, with eligibility assessed during the screening process. If eligible, secondary data related to the critical condition will be extracted from the participant's medical records, including anthropometric data, sociodemographic information, neurological and cardiovascular assessments, current medications, and laboratory test results. The participant's hemodynamic and respiratory stability will be monitored using a multiparameter monitor, recording data such as blood pressure, heart rate, peripheral saturation, and respiratory rate. A cardiorespiratory and clinical safety checklist will also be completed prior to conducting tests for all patients, regardless of whether they are using mechanical ventilation. The instruments used for assessment the muscle strength are the Digital Hand Dynamometer (Saehan Corporation®, DHD-1) and the Hand Held Dynamometer (HOGGAN SCIENTIFIC LLC, microFET2).

Study Type

Observational

Enrollment (Estimated)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • PE
      • Recife, PE, Brazil, 50740-600
        • Recruiting
        • Federal University of Pernambuco (UFPE)
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Lucas Rafael da Silva Fraga
      • Recife, PE, Brazil, 50920-460
        • Not yet recruiting
        • Hospital Otávio de Freitas
        • Contact:
      • Recife, PE, Brazil, 51030-020
        • Recruiting
        • Hospital Nossa Senhora Das Gracas
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Jose Douglas de Souza Cordeiro

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The population comprised adult and elderly individuals of both sexes able to do volitional tests. For the healthy sample, volunteers without barriers to the assessment of peripheral muscle strength will meet the inclusion criteria while, for the critical patient population, the sample will include individuals hospitalized in the Intensive Care Unit (ICU) who also do not have barriers to the assessment.

Description

Inclusion Criteria:

  • Healthy individuals of both sexes
  • Patients and volunteers aged between 18 and 90 years old (youth/adults/elderly).
  • Patients admitted to the ICU.
  • No recent muscle injuries of both limbs for a past 6-months.

Exclusion Criteria:

Patients and volunteers < 20 years and > 90 years

Healthy individuals

  • Unable to follow command completely
  • Severe osteoporosis or neuromuscular disease leading to decreased muscle strength
  • Presence of opened or infectious wound
  • Presence of pain in evaluating muscle groups

Patients in ICU

  • Unable to follow command completely
  • Acute stroke
  • Hip fracture, unstable cervical spine or pathological fracture
  • Recent surgery involving the upper airways, chest, abdomen, or limbs
  • Presence of opened or infectious wound
  • Presence of pain in evaluating muscle groups

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients in the ICU
The ICU sample will comprised patients of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.
Healthy Participants
The healthy sample will comprised volunteers of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peripheral muscle strength measured by hand held dynamometer
Time Frame: Day 1
Strength of the muscles of the upper and lower limbs using a digital hand held dinamometer in healthy individuals and critical patients.
Day 1
Peripheral muscle strength measured by Medical Research Council score
Time Frame: Day 1
Global muscle strength using the Medical Research Council-sum score (MRC score) in healthy individuals and critical patients. The MRC score is obtained by evaluating muscle groups in the upper and lower extremities (wrist extensors, elbow flexors, abductors of the shoulder, dorsal ankle flexors, knee extensors, and hip flexors). For each muscle group will be assigned a score between 0 and 5, and the total score can vary between 0 (worse outcome) up to 60 points (the better outcome).
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peripheral muscle strength measured by hand grip dynamometer
Time Frame: Day 1
Peripheral muscle strength assessed bilaterally through digital handgrip dynamometry in healthy individuals and critical patients.
Day 1
Mobility in ICU measured by Perme Intensive Care Unit Mobility Score
Time Frame: Day 1
The Perme Intensive Care Unit Mobility Score comprises 15 items grouped into 7 categories: (1) mental state, (2) potential barriers to mobility, (3) strength, (4) in bed mobility, (5) transfers, (6) gait and (7) endurance. The minimum score is 0 and the maximum is 32, where the higher the score, the better outcome.
Day 1
Level of frailty in older adults by the Multidimensional Assessment of Older People (AMPI-AB)
Time Frame: Day 1
The AMPI-AB is composed of 17 questions based on well-known and validated scores used to detect relevant geriatric problems, such as lack of social support, multimorbidity, polypharmacy, cognitive and sensory impairment, physical limitations, depression, falls, functional dependence, weight loss and poor oral health. The total score can vary between 0 (the best outcome) up to 21 (the worst outcome) and classifies older adults in low, intermediate or high complexity of care.
Day 1
Level of physical activity in young adults by the International Physical Activity Questionnaire - Short Form
Time Frame: Day 1
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) has 8 items that record the activity of four intensity levels: 1) vigorous-intensity activity such as aerobics, 2) moderate-intensity activity such as leisure cycling, 3) walking, and 4) sitting.
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shirley Campos, University of Pernambuco
  • Study Director: Pedro Vinicius Porfirio, University of Pernambuco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2024

Primary Completion (Estimated)

October 31, 2024

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

February 28, 2024

First Submitted That Met QC Criteria

February 28, 2024

First Posted (Actual)

March 6, 2024

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 6.131.540

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intensive Care Unit

3
Subscribe